Report for: Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

Title	Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
Published in	Trials, June 2022
DOI	10.1186/s13063-022-06360-3
Pubmed ID	35725488
Authors	Etienne Karita, Julien Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Jeannine Mukamuyango, Susan Allen, Amanda Tichacek, Rachel Parker, Frances Priddy, Felix Sayinzoga, Sabin Nsanzimana, Cynthia Robinson, Michael Katwere, Dickson Anumendem, Maarten Leyssen, Malinda Schaefer, Kristin M. Wall

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Unknown	1	100%

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	29	100%

Readers by professional status	Count	As %
Unspecified	4	14%
Student > Doctoral Student	2	7%
Student > Master	2	7%
Lecturer	1	3%
Student > Ph. D. Student	1	3%
Other	3	10%
Unknown	16	55%

Readers by discipline	Count	As %
Design	4	14%
Nursing and Health Professions	3	10%
Pharmacology, Toxicology and Pharmaceutical Science	1	3%
Social Sciences	1	3%
Immunology and Microbiology	1	3%
Other	2	7%
Unknown	17	59%

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized…